Navigation Links
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Date:10/27/2009

TOKYO and SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. ("Astellas") and Medivation, Inc. (Nasdaq: MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. The companies will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.

"We are pleased to initiate a great partnership with Medivation," stated Masafumi Nogimori, president and chief executive officer of Astellas. "We believe that MDV3100 has the unique potential to establish a new treatment approach for prostate cancer. Astellas already has the global expertise in urology and the strong commitment to focus on oncology. This partnership is a significant milestone to further expand our business in urology and to establish our franchise in oncology."

"We are excited t
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
4. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
6. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
7. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
(Date:9/2/2014)... 2014 According to the new ... Analytical, Preparative), by Material (Metal, Glass, Plastic), by Application ... to 2018", published by MarketsandMarkets, the Chiral Chromatography Columns ... poised to grow at a CAGR of 5.2% from ... Browse 90 market data tables and 15 figures ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... present an overview of the company at the Morgan Stanley ... , Presentation date: Tuesday September 9, 2014 ... A live webcast and 30-day archive of this presentation will ... Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... 15 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), ... present a company overview at the 17th Annual NewsMakers in ... 11:00 a.m. ET at the Millennium Broadway Hotel & Conference ... of the presentation will be available on the "Investors & ...
... Md., Oct. 15 /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: ... in China and a producer, marketer and seller of ... that the Company will present at Citi,s Greater China ... the Grand Hyatt Macau.  Management is currently scheduled to ...
Cached Medicine Technology:
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 (HealthDay ... behind the rising rates of type 2 diabetes, according to ... national surveys spanning from 1976 through 2010 to determine how ... by factors such as changing distribution of race, age and ... prevalence of diabetes in men rose from about 5 percent ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
(Date:9/2/2014)... and marijuana may lead to different types of harmful ... analyzed 2007 to 2011 data gathered from more than ... used alcohol or marijuana at least once. The ... unsafe driving, damage to relationships with friends and romantic ... of alcohol, especially among females. On the ...
(Date:9/2/2014)... in locations with less intensive (and expensive) practice patterns ... that spare patients unnecessary and excessive medical care, according ... . , "Growing concern about the costs and harms ... ability to avoid the provision of unnecessary care," said ... and The Dartmouth Institute for Health Policy & ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Residency training predicts physicians' ability to practice conservatively 2
... WASHINGTON, Sept. 18 Americans believe that,providing medical care ... top of our nation,s priorities, in line with resolving ... a new nationwide survey. What,s,more, three-quarters of the public ... military veterans., And what do Americans think should ...
... identified specific damages to the brain that may occur when ... study in mice found that those animals that lived alone ... more damage to neurons in one part of the brain ... studies in humans have shown that socially isolated heart attack ...
... primarily for blind people places a layer of information technology ... interest along their path as they pass them. , The ... of Michigan. Researchers will present their work at two conferences ... A to point B. They learn to count steps if ...
... is almost always adenocarcinoma or signet ring cell carcinoma ... cell carcinoma. We report a patient with adenocarcinoma of ... This is the first reported case of gastric cancer ... to be published on 28 May 2008 in the ...
... numerous randomized clinical trials (RCT) have evaluated, and ... treatment regimens. Surgery remains standard care for early ... have also shown a survival benefit associated with ... patterns of care for these cancers. A study ...
... Introduced, MINNEAPOLIS, Sept. 17 Today ClearWay ... Board Members and,thanked outgoing members for their service ... and Executive Director of the Honeywell,Foundation as well ... affairs for Honeywell, was elected as the new ...
Cached Medicine News:Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 2Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 3Health News:Study suggests why heart attack victims do better with social support 2Health News:Study suggests why heart attack victims do better with social support 3Health News:New Bluetooth system orients blind and sighted pedestrians 2Health News:New Bluetooth system orients blind and sighted pedestrians 3Health News:How to treat gastroesophageal adenocarcinom patients? 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: